Unknown

Dataset Information

0

Docking to RNA via root-mean-square-deviation-driven energy minimization with flexible ligands and flexible targets.


ABSTRACT: Structure-based drug design is now well-established for proteins as a key first step in the lengthy process of developing new drugs. In many ways, RNA may be a better target to treat disease than a protein because it is upstream in the translation pathway, so inhibiting a single mRNA molecule could prevent the production of thousands of protein gene products. Virtual screening is often the starting point for structure-based drug design. However, computational docking of a small molecule to RNA seems to be more challenging than that to protein due to the higher intrinsic flexibility and highly charged structure of RNA. Previous attempts at docking to RNA showed the need for a new approach. We present here a novel algorithm using molecular simulation techniques to account for both nucleic acid and ligand flexibility. In this approach, with both the ligand and the receptor permitted some flexibility, they can bind one another via an induced fit, as the flexible ligand probes the surface of the receptor. A possible ligand can explore a low-energy path at the surface of the receptor by carrying out energy minimization with root-mean-square-distance constraints. Our procedure was tested on 57 RNA complexes (33 crystal and 24 NMR structures); this is the largest data set to date to reproduce experimental RNA binding poses. With our procedure, the lowest-energy conformations reproduced the experimental binding poses within an atomic root-mean-square deviation of 2.5 A for 74% of tested complexes.

SUBMITTER: Guilbert C 

PROVIDER: S-EPMC2910576 | biostudies-literature | 2008 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Docking to RNA via root-mean-square-deviation-driven energy minimization with flexible ligands and flexible targets.

Guilbert Christophe C   James Thomas L TL  

Journal of chemical information and modeling 20080530 6


Structure-based drug design is now well-established for proteins as a key first step in the lengthy process of developing new drugs. In many ways, RNA may be a better target to treat disease than a protein because it is upstream in the translation pathway, so inhibiting a single mRNA molecule could prevent the production of thousands of protein gene products. Virtual screening is often the starting point for structure-based drug design. However, computational docking of a small molecule to RNA s  ...[more]

Similar Datasets

| S-EPMC3324767 | biostudies-literature
| S-EPMC2830444 | biostudies-literature
| S-EPMC3087690 | biostudies-literature
| S-EPMC4606885 | biostudies-literature
| S-EPMC2374114 | biostudies-literature
| S-EPMC6871058 | biostudies-literature
| S-EPMC2947618 | biostudies-literature
| S-EPMC6184633 | biostudies-literature